De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You (DIGNITY)

Weill Cornell Medicine (WCM)

Status: Enrolling

Conditions: Breast Cancer

Treatments: Procedure: Live Biobank

Study type: Observational

Funder types: Other

Identifiers

NCT05134779

21-06023682

Details and patient eligibility

About

This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.

Full description

To test this hypothesis the investigators will focus on studying BC patients using an innovative approach, the DIGNITY Study (De-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you) designed to building a live tissue biobank of Patient Derived Tumor Organoids (PDOs) derived from tumor at surgery, preceded or not by neoadjuvant therapy (NAT), and at recurrence/metastasis. BC patients enrolled in this study are consented to enable investigators to generate a biobank of tumor tissue (obtained from surgically removed excess that would otherwise be disposed off ) and matched blood cells ( obtained from an already existing line or a venipuncture ordered per standard of care testing) at key timepoints in their treatment course.

Enrollment: 400 estimated patients

Sex: Female

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients will historically proven BC are eligible to be on the study

Exclusion criteria

• Carriers of other cancers other than breast.

Trial design

400 participants in 1 patient group

Cohort 1

Description:

Patients with breast cancer (BC), any stage will be considered for this study.

Treatment:

Procedure: Live Biobank